MS
CADL icon

Maven Securities’s Candel Therapeutics CADL Stock Holding History

Maven Securities’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-51,731
Closed -$449K – 803
2024
Q4 		$449K Buy
+51,731
New +$306K 0.01% 605

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Maven Securities's CADL Position: Q1 2025 in Review

Maven Securities sold out of Candel Therapeutics (CADL) in Q1 2025, closing a stake of 51,731 shares — an estimated $449K sold.

Maven Securities first reported a position in CADL in Q4 2024 and held it in 1 quarter. The position peaked at $449K in Q4 2024. 82 funds tracked by Wall St. Rank hold CADL as of Q1 2025.

  • Maven Securities reported no remaining Candel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Maven Securities sold 51,731 Candel Therapeutics shares in Q1 2025, an estimated $449K.
  • Maven Securities first reported a position in Candel Therapeutics in Q4 2024 and held it in 1 quarter.
  • Maven Securities's Candel Therapeutics position peaked at $449K in Q4 2024.
  • 82 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2025.

Based on Maven Securities's 13F filing for Q1 2025, filed 14 May 2025.